- Report
- March 2025
- 50 Pages
Global
From €2519EUR$2,650USD£2,116GBP
- Report
- May 2024
- 128 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- September 2023
- 120 Pages
North America
From €5656EUR$5,950USD£4,752GBP
- Report
- February 2024
- 125 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- May 2022
- 163 Pages
Global
From €3422EUR$3,600USD£2,875GBP
- Report
- March 2022
- 180 Pages
Global
From €3422EUR$3,600USD£2,875GBP
- Report
- March 2025
- 50 Pages
Global
From €2519EUR$2,650USD£2,116GBP
- Report
- November 2021
- 600 Pages
Global
From €3803EUR$4,000USD£3,195GBP
Oxymorphone is an opioid analgesic drug used to treat moderate to severe pain. It is a semi-synthetic opioid derived from thebaine, an alkaloid found in the opium poppy. Oxymorphone is available in both immediate-release and extended-release formulations. The immediate-release formulation is used for the relief of acute pain, while the extended-release formulation is used for the management of chronic pain. Oxymorphone is typically prescribed for patients who have not responded to other analgesics, such as non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen.
Oxymorphone is a controlled substance in many countries, and its use is subject to strict regulations. It is important to note that oxymorphone is highly addictive and can lead to physical and psychological dependence.
Companies in the oxymorphone market include Purdue Pharma, Endo Pharmaceuticals, Teva Pharmaceuticals, and Mylan Pharmaceuticals. Show Less Read more